UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

S982 Association of Histologic-Endoscopic Response and Long-Term Clinical Outcomes: Results From Phase 2 Mirikizumab Trial in Patients With Moderately-to-Severely Active Crohn’s Disease

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S740-S741

2023

Link zum Volltext

Verfügbarkeit prüfen

S970 Efficacy and Safety of Mirikizumab in Patients With Crohn’s Disease: 104-Week Extension Results From a Phase 2 Randomized Controlled Trial

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S731-S731

2023

Link zum Volltext

Verfügbarkeit prüfen

S754 Impact of Mirikizumab Treatment on Health-Related Quality of Life in Patients With Crohn’s Disease: A Phase 2 Study Analysis Using the SF-36

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e534-e535

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

Journal of the American Academy of Dermatology, 2016-12, Vol.75 (6), p.1156-1161

2016

Link zum Volltext

Verfügbarkeit prüfen

S783 Improvement in Fatigue With Mirikizumab Therapy Is Associated With Improvements in Patient-Reported Outcomes in Patients With Moderately-to-Severely Active Crohn’s Disease

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e557-e558

2022

Link zum Volltext

Verfügbarkeit prüfen

S834 Improvement in Fatigue With Mirikizumab Therapy Is Associated With Clinical Remission and Pain Improvements but Not With Endoscopic Response in Patients With Moderately-to-Severely Active Crohn’s Disease

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e602-e603

2022

Link zum Volltext

Verfügbarkeit prüfen

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

Quality of life research, 2020-02, Vol.29 (2), p.369-380

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Annals of the rheumatic diseases, 2020-02, Vol.79 (2), p.176

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

Clinical gastroenterology and hepatology, 2023-11

2023

Link zum Volltext

Verfügbarkeit prüfen

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years

Journal of rheumatology, 2022-03, Vol.49 (3), p.265

2022

Link zum Volltext

Verfügbarkeit prüfen

Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions

Journal of Crohn's and colitis, 2023-07, Vol.17 (7), p.1066-1078

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

Journal of rheumatology, 2016-02, Vol.43 (2), p.289

2016

Link zum Volltext

Verfügbarkeit prüfen

Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis

The Lancet. Rheumatology, 2022-09, Vol.4 (9), p.e626-e634

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Arthritis & rheumatology (Hoboken, N.J.), 2019-03, Vol.71 (4), p.599-611

2019

Link zum Volltext

Verfügbarkeit prüfen

HEPATOTOXICITY FOLLOWING NEVIRAPINE-CONTAINING REGIMENS IN HIV-1-INFECTED INDIVIDUALS

Pharmacological research, 2002-09, Vol.46 (3), p.295-300

2002

Link zum Volltext

Verfügbarkeit prüfen

The Steady-State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected Persons

The Journal of infectious diseases, 2001-07, Vol.184 (1), p.37-42

2001

Link zum Volltext

Verfügbarkeit prüfen

Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine

AIDS (London), 2001-12, Vol.15 (18), p.2423-2429

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(9)

Publikationsform

Artikel
(17)

Sprache

Englisch
(17)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Male
(8)
Adult
(6)
Female
(6)
Crohns Disease
(5)
Endoscopy
(5)
Middle Aged
(5)
Rheumatology
(4)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(3)
Double-Blind Method
(3)
Gastroenterology
(3)
Hiv Infections - Drug Therapy
(3)
Nevirapine
(3)
Patients
(3)
Psoriasis
(3)
Quality Of Life
(3)
Spondylarthritis - Diagnostic Imaging
(3)
Treatment Outcome
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S982 Association of Histologic-Endoscopic Response and Long-Term Clinical Outcomes: Results From Phase 2 Mirikizumab Trial in Patients With Moderately-to-Severely Active Crohn’s Disease

S970 Efficacy and Safety of Mirikizumab in Patients With Crohn’s Disease: 104-Week Extension Results From a Phase 2 Randomized Controlled Trial

S754 Impact of Mirikizumab Treatment on Health-Related Quality of Life in Patients With Crohn’s Disease: A Phase 2 Study Analysis Using the SF-36

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

S783 Improvement in Fatigue With Mirikizumab Therapy Is Associated With Improvements in Patient-Reported Outcomes in Patients With Moderately-to-Severely Active Crohn’s Disease

S834 Improvement in Fatigue With Mirikizumab Therapy Is Associated With Clinical Remission and Pain Improvements but Not With Endoscopic Response in Patients With Moderately-to-Severely Active Crohn’s Disease

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years

Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

HEPATOTOXICITY FOLLOWING NEVIRAPINE-CONTAINING REGIMENS IN HIV-1-INFECTED INDIVIDUALS

The Steady-State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected Persons

Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine

Suchergebnisse filtern